Advertisement

Topics

Latest "Stoke Therapeutics, Inc." News Stories

00:50 EST 22nd February 2019 | BioPortfolio

Here are the most relevant search results for "Stoke Therapeutics, Inc." found in our extensive news archives from over 250 global news sources.

More Information about Stoke Therapeutics, Inc. on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Stoke Therapeutics, Inc. for you to read. Along with our medical data and news we also list Stoke Therapeutics, Inc. Clinical Trials, which are updated daily. BioPortfolio also has a large database of Stoke Therapeutics, Inc. Companies for you to search.

Showing "Stoke Therapeutics" News Articles 1–25 of 8,100+

Thursday 21st February 2019

Halozyme Therapeutics, Inc. (HALO) CEO Dr. Helen Torley on Q4 2018 Results - Earnings Call Transcript


Moderna to Report Fourth Quarter and Full Year 2018 Financial Results on Wednesday, March 6, 2019

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, March 6, 2019 to report its fourth quarter and full year 2018 ...

Anika Reports Fourth Quarter and Full Year 2018 Financial Results

Strong Bottom Line Performance with $0.54 Diluted EPS for Fourth Quarter of 2018 MONOVISC and CINGAL Global Revenue Increased 14% for Full Year of 2018 Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic and regenerative medicines company specializing in therapeutics b


Tomorrow, FDA will post meeting materials for Tuesday's meeting of the Oncologic Drugs AdComm. #ODAC will review Karyopharm Therapeutics' #selinexor tablets, which is proposed for treatment of certain patients w/ relapsed refractory multiple myeloma. $KPT

Tomorrow, FDA will post meeting materials for Tuesday's meeting of the Oncologic Drugs AdComm. #ODAC will review Karyopharm Therapeutics' #selinexor tablets, which is proposed for treatment of certain patients w/ relapsed refractory multiple myeloma. $KPTI https://www.fda.gov/AdvisoryCommittee

Cerevel Therapeutics Taps Otsuka’s Sanchez for Chief Medical Officer

Raymond Sanchez has been appointed chief medical officer of Cerevel Therapeutics. Sanchez comes to Boston-based Cerevel from Otsuka Pharmaceutical Development and Commercialization, where he most recently served as senior vice president, global clinical development. During the last half of his 11-year tenure at Otsuka, he was also chief medical officer of Otsuka subsidiary Avanir Pharmaceuticals. ...

The HOX Hypothesis: A Novel Approach To Targeted Cancer Therapy

Emerging Company Profile: With a Phase I clinical trial starting in Q3 and Series A funding to raise, HOX Therapeutics...   

Moderna’s gamble: what’s behind biotech’s biggest-ever IPO?

In December last year, Cambridge, Massachusetts-based Moderna Therapeutics smashed the record for the biotech industry’s largest initial public offering (IPO)....Read More... The post Moderna’s gamble: what’s behind biotech’s biggest-ever IPO? appeared first on Pharmaceutical Technology.

Kedalion Therapeutics Broadens Leadership Team and Expands Scientific Advisory Board

Kedalion Therapeutics, Inc., a clinical-stage company focused on the development and commercialization of topical ophthalmology therapies based on its proprietary AcuStream™ platform, today announced the hiring of Casey Dougan to its management team as Vice President of Corporate Development, as well as the addition of Richard L. Lindstrom, M.D., and Joh...

ADDING MULTIMEDIA Dicerna Bolsters Leadership Team to Support Continued Growth

— Regina DeTore Paglia Joins Company as Senior Vice President of Human Resources — — Rebecca Peterson Hired as Head of Corporate Communications — — Hardean E. Achneck, M.D., Joins as Vice President, Head of Medical Development — Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigatio...

Oyster Point Pharma to Present at the 8th Annual SVB Leerink Global Healthcare Conference

Oyster Point Pharma, Inc., a privately held clinical-stage pharmaceutical company with an initial focus on developing novel therapies for the treatment of Dry Eye Disease, today announced that Jeffrey Nau, Ph.D., M.M.S, President and CEO, is scheduled to present a corporate overview at the 8th Annual SVB Leerink Global Healthcare Conference on Wednesday, F...

iSchemaView’s RAPID™ Approved for Use in Brazil

iSchemaView Expands RAPID’s South American Footprint by Bringing Brazil the Only Clinically Validated, Next-Generation Imaging Platform for Assessing Ischemic Stroke iSchemaView, the worldwide leader in advanced imaging for stroke, has received approval from ANVISA (the Brazilian Health Regulatory Agency), for the use of the RAPID imaging platform ac...

Reminder: Ligand to Host Analyst Day on March 12th in New York City

Event to feature business updates and presentations by four corporate partners Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will host an Analyst Day on Tuesday, March 12, 2019 from 10:00 a.m. to 12:00 p.m. Eastern time (7:00 a.m. to 9:00 a.m. Pacific time) in New York City. Company presenters will include John Higgins, CEO, Matt Foehr, C...

Magenta Therapeutics Presents Preclinical Data on MGTA-145, First-Line Stem Cell Mobilization Product Candidate for Autologous and Allogeneic Bone Marrow Transplant

-- A single dose of MGTA-145 plus plerixafor mobilized two to three times more stem cells in non-human primates than multi-day regimen of current standard of care G-CSF -- -- Cells mobilized with MGTA-145 plus plerixafor rapidly engrafted in non-human primates following autologous transplant -- -- MGTA-145-mobilized cells from non-human p...

Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host a conference call on Thursday, February 28, 2019, at 5:00 p.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2018, and recent operational highlights. ...

Millendo Therapeutics, Inc. to Present at the 8th Annual SVB Leerink Global Healthcare Conference

Millendo Therapeutics, Inc. (Nasdaq: MLND), a clinical-stage biopharmaceutical company developing novel treatments for orphan endocrine diseases, announced today that Julia C. Owens, Ph.D., President and Chief Executive Officer, will present at the 8th Annual SVB

Rainier Therapeutics to Participate in the SVB Leerink Global Healthcare Conference

Rainier Therapeutics, Inc., a privately-held clinical stage drug development company, today announced that Scott Myers, Chairman and Chief Executive Officer, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 27, 2019 at 1:30 p.m. ET (10:30 a.m. PT) at the Lotte New York Palace in New York City. About Ra...

$CRSP Proposes New Members to the Board of Directors https://finance.yahoo.com/news/crispr-therapeutics-proposes-members-board-120000589.html …

$CRSP Proposes New Members to the Board of Directors https://finance.yahoo.com/news/crispr-therapeutics-proposes-members-board-120000589.html …

Relief of Heartburn in Patients With Erosive Esophagitis

Does a new potassium-competitive acid blocker, vonoprazan, provide more rapid relief of heartburn than standard treatment with a proton-pump inhibitor? Alimentary Pharmacology & Therapeutics

ArQule to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Brian Schwartz, M.D., Chief Medical Officer and Head of Research and Development, of ArQule will present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019, at 11:30 a.m. ET at the Lotte New York Palace in New York City. The...

ArQule to Report Fourth Quarter and Full Year 2018 Financial Results on March 7, 2019

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the fourth quarter and full year of 2018 before the market opens on Thursday, March 7, 2019. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and provide a general business update. The live webcast can be acc...

Ra Pharmaceuticals to Present at the 8th Annual SVB Leerink Global Healthcare Conference

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that Ramin Farzaneh-Far, M.D., Chief Medical Officer of Ra Pharma, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Thursday, February 28, 2019 at 2:30 p.m. E.T. The conference is being held at the Lotte New York Palace, New York, NY. The presentation will be webcast ...

Landos Biopharma Announces Publication Supporting Novel, Dual Mechanism of Action for BT-11 in Models of IBD

Landos Biopharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases, announced the publication of findings that further elucidate the regulatory arm of the novel mechanism of action for BT-11, its investigational new

MPM Capital Raises $400 Million to Fund Early-Stage Biotech Innovation

MPM Capital, a life-sciences venture capital firm investing in early-stage therapeutics companies, announced today the closing of its seventh venture fund, BioVentures 2018 (BV2018). MPM is currently investing out of BV2018 and its two oncology-only funds with a total of over $1 billion in capital. With BV2018, MPM will continue to create and inve...

Dicerna Bolsters Leadership Team to Support Continued Growth

— Regina DeTore Paglia Joins Company as Senior Vice President of Human Resources — — Rebecca Peterson Hired as Head of Corporate Communications — — Hardean E. Achneck, M.D., Joins as Vice President, Head of Medical Development — Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigatio...

$FPRX Doses First Patient in Phase 1b Trial of FPA150 immuno-oncology antibody that targets B7-H4 https://www.businesswire.com/news/home/20190220006026/en/Prime-Therapeutics-Doses-Patient-Phase-1b-Trial …

$FPRX Doses First Patient in Phase 1b Trial of FPA150 immuno-oncology antibody that targets B7-H4 https://www.businesswire.com/news/home/20190220006026/en/Prime-Therapeutics-Doses-Patient-Phase-1b-Trial …


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks